• Stephen A Klassen, Jonathon W Senefeld, Patrick W Johnson, Rickey E Carter, Chad C Wiggins, Shmuel Shoham, Brenda J Grossman, Jeffrey P Henderson, James Musser, Eric Salazar, William R Hartman, Nicole M Bouvier, Sean T H Liu, Liise-Anne Pirofski, Sarah E Baker, Noud van Helmond, R Scott Wright, DeLisa Fairweather, Katelyn A Bruno, Zhen Wang, Nigel S Paneth, Arturo Casadevall, and Michael J Joyner.
• Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.
• Mayo Clin. Proc. 2021 May 1; 96 (5): 126212751262-1275.

AbstractTo determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized patients with COVID-19.Copyright © 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

12 keywords...

hide…